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We studied the effects of 17b-estradiol, progesterone,
and dihydrotestosterone on in vitro growth of human
metastatic melanoma. Each sex hormone inhibited
the growth of melanoma receptor-dependently;
17b-estradiol inhibited 3H-thymidine uptake of estro-
gen receptor-positive WM266-4 and NM26, but not
that of the receptor-negative HS15. Progesterone
inhibited 3H-thymidine uptake of progesterone
receptor-positive WM266-4 and HS15, but not that
of the receptor-negative NM26. Dihydrotestosterone
inhibited 3H-thymidine uptake of androgen recep-
tor-positive HS15 and NM26, but not that of the
receptor-negative WM266-4. The growth inhibition
by each hormone was counteracted by the respective
hormone receptor antagonist. The combination of
more than two hormones neither gave additive nor
synergistic growth inhibition. The growth inhibition
by each sex hormone was counteracted by inter-
leukin-8 but not by the other growth factors. Each
sex hormone reduced the constitutive interleukin-8
secretion and mRNA levels in the respective recep-
tor-positive melanoma but not in the receptor-nega-
tive melanoma. Transient transfection showed that
each sex hormone inhibited the constitutive chlor-
amphenicol acetyltransferase expression driven by
interleukin-8 promoter in the respective receptor-
positive melanoma but not in the receptor-negative
melanoma. Transfection with a series of 5¢-deleted
interleukin-8 promoter/chloramphenicol acetyltrans-
ferase reporter constructs demonstrated that the
sequences between ± 98 and ± 63 bp on interleukin-8
promoter may be involved in the transcriptional
repression. These data suggest that 17b-estradiol,
progesterone, and dihydrotestosterone suppress the
growth of melanoma by inhibiting interleukin-8 pro-
duction in a receptor-dependent manner. Key words:
receptor/sex hormone/transcription. J Invest Dermatol
117:274±283, 2001
I
t has long been suggested that sex hormones modulate the
growth of malignant melanoma. Mutually con¯icting data
are reported, however; melanomas seemed to metastasize
more slowly in women than in men (Shaw et al, 1978), and
survival after metastasis was longer in women than in men
(Rampen, 1980). These data indicate the growth inhibition by
estrogen or progesterone and/or growth stimulation by androgens
on melanoma. In contrast, for stage II melanoma, a lower survival
rate was observed in pregnant women than in nonpregnant women
with melanoma (Shiu et al, 1976). Early studies also reported the
occurrence, rapid enlargement, or frequent metastasis of melanoma
during pregnancy (Pack and Scharnagel, 1951). These reports
suggest the growth stimulation by estrogen and/or progesterone on
melanoma; however, it is still controversial if pregnancy affects the
growth of melanoma. Holly (1986) summarized the etiologic
studies and reported that 10 of 11 studies showed no survival
difference between women with melanoma associated with
pregnancy and those with no association, indicating few deleterious
effects of pregnancy on the survival. Wong et al (1989), Mackie
et al (1991), and Driscoll et al (1993) also suggested that pregnancy
may have no effects on the outcome of patients with melanoma.
Various experimental results for the hormonal growth regulation
on melanoma are confusing and inconclusive; estrogen in vivo
inhibited the growth of hamster HM-1 melanoma (Schleicher et al,
1987) or human melanoma UISO-MEL-2 (Feucht et al, 1988)
grafted in athymic mice. Melanoma B16 grew more slowly in
normal female mice than oophorectomized female or male mice
(Proctor et al, 1976). These data support the inhibitory effect of
estrogen on the in vivo growth of melanoma. Some data denied the
growth-regulatory effect of estrogen, however; estrogen did not
alter the in vitro growth of S91 mouse melanoma B line cells or
human melanoma cell lines UISO-MEL-1, 2, and 4 (Cobb and
McGrath, 1974; Feucht et al, 1988), and there were no differences
in the growth rate of B16 between pregnant and nonpregnant
female mice (Proctor et al, 1976). On the other hand, several
studies suggest the growth-stimulatory effects of estrogen; estrogen
enhanced in vivo growth and lung metastasis of B16 in mice in a
concentration-dependent manner (Lopez et al, 1978). Melanoma
grew larger in normal female hamsters than in oophorectomized
females (Rosenberg et al, 1963). Thus the hormonal growth
regulation on melanoma seems highly complicated and may
involve a variety of elements in melanoma itself and tumor-
surrounding or distant tissues or organs. One of such elements is the
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presence or absence of the respective hormone receptors. The
incidence of estrogen receptor (ER) is reported to be 9±79%
(Walker et al, 1987; Cohen et al, 1990) and that of progesterone
receptor (PR) is 21±44% (Neifeld and Lippman, 1980; Karakousis
et al, 1980), and that of androgen receptor (AR) is 15±17% (Neifeld
and Lippman, 1980) in melanoma by radiolabeled ligand binding
assays using dextran-coated charcoal. Owing to the high false
positivity of the binding assays (Cohen et al, 1990), however,
different methods have been recently used for the detection of
hormone receptors; western blotting (Swami et al, 2000), im-
munohistochemical methods (Cohen et al, 1990; Duncan et al,
1994), or enzyme immunoassays (Kuenen-Boumeester et al, 1996).
Even with the improved methods, however, different papers still
report different results on the incidence of hormone receptor,
possibly because different laboratories may use different anti-
hormone receptor antibodies, or because the presence or absence of
hormone receptor may depend on tumor location in the whole
body or tumor activation status. Ferno et al (1987) reported that
ER was positive in 56% of metastatic melanoma by enzyme
immunoassay, whereas Cohen et al (1990) showed that ER was
negative in all 33 primary and metastatic melanoma by immuno-
histochemistry.
Previous studies support that metastatic melanoma constitutively
produces a variety of growth factors and thus regulates its own
growth in an autocrine manner (Herlyn, 1990). The mRNA or
protein expression in melanoma is reported for basic ®broblast
growth factor (bFGF), interleukin (IL) -8, melanocyte growth
stimulatory activity/growth-regulated protein (GRO) -a platelet-
derived growth factor (PDGF), etc. (Herlyn, 1990), and the pattern
of the expression is heterogeneous among various melanoma cells.
It is thus hypothesized that sex hormones may upregulate or
downregulate the autocrine production of growth factors in certain
melanoma cells and thus regulate their growth.
In this study, we aimed to examine the growth-regulatory effects
of sex hormones, 17b-estradiol (E2), progesterone, and dihydro-
testosterone (DHT) in human metastatic melanoma cell lines. We
further examined the mechanism for the growth-regulatory effects
of these sex hormones, focusing on their effects on autocrine
production of growth factors.
MATERIALS AND METHODS
Cell lines and maintenance Metastatic melanoma cell line WM266-4
obtained from a female patient was purchased from Dainippon
Pharmaceutical (Osaka, Japan). HS15 and NM26 were removed from
metastatic lymph nodes of male patients, and were established by a
monolayer system as described (Carey et al, 1976; Baker et al, 1986).
Brie¯y, biopsy specimens were dissected free of adherent normal tissues,
and ®nely minced. The resulting cell suspensions were washed,
resuspendend in culture medium, then inoculated into 35 mm diameter
dishes, cultured at 37°C in a humidi®ed atmosphere of 5% CO2, and fed
twice weekly. Con¯uent culture was trypsinized, and expanded into
larger dishes or ¯asks. The subculture was performed once a week.
Human breast cancer MCF-7 cells were purchased from Dainippon.
These cell lines were cultured in Dulbecco's modi®ed Eagle medium
(Gibco-BRL, Grand Island, NY) supplemented with 10% fetal bovine
serum (Gibco-BRL), 1% nonessential amino acids, 1 mM sodium
pyruvate (ICN Biomedicals, Aurora, OH), and 100 U per ml penicillin
G, 100 mg per ml streptomycin, 0.25 mg per ml amphotericin B (Gibco-
BRL). Human prostate cancer LNCaP cells were purchased from
Dainippon, and were maintained in RPMI 1640 (GIBCO-BRL)
supplemented with 10% fetal bovine serum.
Reagents E2, 17a-estradiol, progesterone, pregnenolone, DHT, and b-
dihydrotestosterone were purchased from Sigma (St Louis, MO). ICI
182,780, bicalutamide were obtained from Zeneca Pharmaceuticals
(Maccles®eld, U.K.). RU486 was from Schering AG (Berlin, Germany).
These agents were dissolved in ethanol as 10 mM stock solution and were
kept in the dark until used. Recombinant human IL-8 was from Sigma.
Recombinant human GRO-a was from Pepro Tech EC (London, U.K.).
Mouse IgG monoclonal anti-human IL-8 antibody was from BioSource
International (Camarillo, CA), and was speci®c to natural and
recombinant human IL-8, with no cross-reactivity to human or mouse
GRO-a, GRO-b, or GRO-g. Human recombinant PDGF-AB was from
Carbiochem-Novabiochem Corp. (San Diego CA). Recombinant human
IL-6 was from Boehringer Mannheim (Indianapolis, IN). Recombinant
human bFGF was from Becton Dickinson (San Jose, CA). Control mouse
IgG was from Dako Corp. (Carpinteria, CA).
Hormone-binding studies Melanoma cells were harvested and lyzed.
The cytosolic fractions were separated, and used for radiolabeled ligand
binding assays as described (Feucht et al, 1988; Pottratz et al, 1994). The
protein concentration of cytosolic preparation was determined using a
Bio-Rad protein assay kit (Hercules, CA). Aliquots of the fractions were
incubated at 4°C for 3 h with 0.05±1.0 nM 3H-E2 (Amersham Corp.,
Arlington Heights, IL), 3H-R5020 (New England Nuclear, Cambridge,
MA), or 3H-R1881 (New England Nuclear) for ER, PR, or AR
measurements, respectively. One hundred-fold excess of nonradioactive
hormone was used to correct for nonspeci®c binding. Bound and free
hormones were separated using dextran-coated charcoal, and speci®c
binding was determined as described (Feucht et al, 1988). Binding
constants, Kd and Bmax, were calculated according to the method of
Scatchard (Scatchard, 1949).
Western blot Aliquots (50 mg protein) of the extracts from melanoma,
MCF-7, and LNCaP cells were resolved by sodium dodecyl sulfate±
polyacrylamide (8%) gel electrophoresis under nonreducing conditions.
The proteins were electrotransferred on to nitrocellulose membranes as
described (Zhu et al, 1999; Swami et al, 2000). After blocking with 5%
nonfat dry milk, membranes were probed for 2 h with 10 mg per sheet
primary antibodies: mouse monoclonal IgG1 anti-ERa C-314 (Santa
Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal IgG anti-PR
H-190 (Santa Cruz Biotechnology), or rabbit polyclonal IgG anti-AR
N-20 (Santa Cruz Biotechnology). The blots were washed and incubated
for 60 min with second antibodies: peroxidase-conjugated goat anti-
mouse IgG or anti-rabbit IgG (Pierce, Rockford, IL). After three washes,
immunoreactive bands were detected using an enhanced chemi-
luminescence kit (Amersham).
Proliferation assays WM266-4, HS15, and NM26 cells were plated at
5 3 103 cells per well in triplicate in ¯at-bottomed 96-well plates in
100 ml of culture medium and adhered for 18 h. The medium was
discarded and the plates were washed with phosphate-buffered saline
three times, then incubated with sex hormones and/or recombinant
cytokines at the indicated concentrations in 100 ml per well of serum-
free, phenol red-free Dulbecco's modi®ed Eagle medium for 20 h. Then
0.5 mCi per well of 3H-thymidine (Amersham) was added and the cells
were incubated for an additional 4 h prior to harvest. The incorporation
of 3H-thymidine was assayed by liquid scintillation.
Measurement of cytokines To measure the secretion of cytokines,
melanoma cells were plated in triplicate at 5 3 104 per well in 24-well
plates, adhered overnight, washed, and incubated with sex hormones in
1 ml per well of phenol red-free, serum-free medium for 24 h, and the
culture supernatants were harvested and stored at ±70°C until used. The
activity of IL-6 and IL-8 in the supernatants was measured by an
enzyme-linked immunosorbent assay (ELISA) kit (Biosource), that of
GRO-a and bFGF was measured by ELISA kits (R&D Systems,
Minneapolis, MN), and that of PDGF-AB was measured by ELISA kit
(Genzyme Techne, Minneapolis, MN), according to the manufacturers'
instructions. The sensitivity of the assay for IL-6, IL-8, GRO-a, bFGF,
or PDGF-AB was 2, 5, 10, 3, or 8.4 pg per ml, respectively.
For the analysis of cytokine mRNA expression, northern blot was
performed as described (Zachariae et al, 1991). Melanoma cells were
incubated with sex hormones as above for 8 h, and were harvested.
Total RNA was extracted from the harvested cells by guanidium
isothiocyanate method (Ultraspec, Houston, TX). RNA (25 mg) was
electrophoresed in a 1% agarose gel and was transferred to nitrocellulose
membranes. Blots were hybridized with a 32P-labeled cDNA probe for
human IL-8, which was 0.45 kb EcoRI±EcoRI fragment (Mukaida et al,
1989). To control for differences in RNA sample loading and transfer,
the blots were also hybridized with a 32P-labeled, 1.8 kb HindIII±HindIII
fragment of the gene encoding human b-actin. The membranes were
exposed to X-ray ®lms (Hyper®lm MP; Amersham) for 17 h at ±80°C.
Autoradiograms were scanned using a Molecular Dynamics computing
densitometer (model 300 A; Molecular Devices, Menlo Park, CA). IL-8
mRNA levels were normalized to those of b-actin.
Plasmids and transfection pCAT3-basic vector carrying two SV40
poly(A) signals, one downstream of the chloramphenicol acetyl transferase
(CAT) reporter gene, and the other upstream of the multicloning site was
purchased from Promega (Madison, WI). The HincII±HindIII fragment of
the genomic IL-8 DNA, which spans nucleotides ±546 to +44 bp relative
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to the transcriptional start site (Mukaida et al, 1989), was subcloned into
PUC19, treated with appropriate restriction endonucleases and further
subcloned into pCAT3-basic vector (Dorn and Derse, 1988; Mukaida
et al, 1989). cDNA encoding human ER (1.8 kb) (Green et al, 1986), PR
(4.4 kb) (Kastner et al, 1990), and AR (3.2kb) (Brinkmann et al, 1989)
were subcloned into EcoRI site of pSG5 (Stratagene, La Jolla, CA),
downstream of T7 promoter as described (Green et al, 1988) to produce
expression plasmids for ER, PR, and AR, respectively. The carboxyl-
terminal-truncated mutant plasmids for ER, PR, and AR were generated
by cutting the wild-type plasmids with restriction enzymes, inserting
oligonucleotides with translation stop codons, and religating the vectors as
described (Kastner et al, 1990; Simental et al, 1991; Stein and Yang, 1995).
Transfection of melanoma cells was carried out by the calcium
coprecipitation method using CellPhect transfection kit (Amersham)
according to the manufacturer's instruction. Brie¯y, 1 d before the
experiment, con¯uent cultures of melanoma cells were trypsinized, and
cells were seeded at 1 3 106 cells per 100 mm diameter dish and
incubated overnight at 37°C. The cultures were replenished with fresh
medium and kept at 37°C for 4 h before transfection. The cells were
incubated for an additional 4 h with the DNA-calcium precipitate
containing 10 mg pIL-8 CAT. In some experiments, the cells were
cotransfected with either 5 mg of empty vector pSG5 or 5 mg of wild-type
or mutant hormone receptor expression plasmid together with pIL-8
CAT. The cultures were then glycerol shocked and replenished with fresh
medium. After 3 h, the cells were trypsinized and subdivided into 24-well
plates at 5 3 104 cells per well and incubated in 1 ml per well of culture
Figure 2. The inhibitory effects of E2, progesterone, and DHT on the proliferation of melanoma cell lines. (a, d) E2, (b, e) progesterone, (c,
f) DHT. WM266-4, HS15, and NM26 cells were incubated with E2, progesterone, or DHT at the indicated concentrations and were pulsed with 3H-
thymidine before harvesting as described in Materials and Methods. The data are shown as percentage vs 3H-thymidine uptake of control cultures with
medium alone. In parallel experiments, 17a-estradiol (a), pregnenolone (b), or b-dihydrotestosterone (c) was added to the melanoma cells, and 3H-
thymidine uptake was analyzed. In (d±f), melanoma cells were treated with E2 (10±9 M) in the presence or absence of indicated concentrations of ICI
182,780, or treated with progesterone (10±9 M) in the presence or absence of indicated concentrations of RU486, or treated with DHT (10±8 M) in
the presence or absence of indicated concentrations of bicaltamide. Results represent the mean 6 SEM of four separate experiments. *p < 0.05 vs
control cultures with medium alone, by analysis of variance with Dunnet's multiple comparison test in (a±c). *p < 0.05 vs cultures with E2,
progesterone, or DHT alone, by analysis of variance with Dunnet's multiple comparison test in (d±f). The values of 3H-thymidine uptake in control
cultures with medium alone were mean 6 SEM (n = 4) 18,536 6 1523, 15,231 6 1324, and 10,324 6 1094 cpm for WM266-4, HS15, and NM26
cells, respectively.
Figure 1. Western blot analysis for ER, PR, and AR in
melanoma cells. The lysates from melanoma WM266-4, HS15, or
NM26 were analyzed for the expression of hormone receptors. The ER,
PR, and AR were identi®ed as 65 kDa, 114 kDa, and 110 kDa band,
respectively. The positive controls were the lysates from human breast
cancer MCF-7 cells for ER and PR, and those from prostate cancer
LNCaP cells for AR.
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medium overnight. This procedure eliminates differences in transfection
ef®ciency as the same construct is used for the transfection of separate
cultures. Then the medium was discarded and the cells were washed with
phosphate-buffered saline, and maintained in serum-free, phenol red-free
medium in the presence or absence of sex hormones at indicated
concentrations. After 24 h, the cells were harvested and lyzed by three
freeze/thaw cycles. The cell lysate was centrifuged and supernatant was
assayed for CAT expression by CAT-ELISA (Roche Diagnostics, Tokyo,
Japan) according to the manufacturer's instructions. Total protein amount
was measured by a Bio-Rad protein assay kit. The CAT expression was
presented as picograms of CAT enzyme synthesized per microgram of
total protein. pCAT3-control vector (Promega) containing SV40 early
promoter and enhancer sequences was used as a positive control, and
promoterless pCAT3-basic vector was used as a negative control. The
expression of wild-type or mutant hormone receptors was analyzed by
Western blot using cell lysate and speci®c antibodies. The hormone-
binding activity of the expressed receptors was analyzed by radiolabeled
ligand binding assays.
Statistical analyses One-way analysis of variance with Dunnet's
multiple comparison test was used for the data in Fig 2. One-way
analysis of variance with Scheffe's multiple comparison test was used for
the data in Figs 3±5, 7, and 8, and Table II.
RESULTS
ER, PR, and AR expression in melanoma cells First, the
presence of sex hormone receptors was analyzed in three different
metastatic melanoma cell lines. As examined by binding assays,
WM266-4 expressed ER and PR, but not AR (Table I). HS15
Table I. The presence of ER, PR, and AR in metastatic melanoma cell linesa
ER PR AR
Kd
(nM)
Bmax
(fmol per mg)
Kd
(nM)
Bmax
(fmol per mg)
Kd
(nM)
Bmax
(fmol per mg)
WM 266-4 0.3 6 60.1b 5.4 6 40.6 0.4 6 60.1 6.5 6 10.7 NDc NDc
HS15 ND ND 0.4 6 0.1 4.8 6 0.5 1.2 6 0.3 4.7 6 0.5
NM26 0.3 6 0.1 3.1 6 0.5 ND ND 1.0 6 0.2 5.5 6 0.6
aThe presence of ER, PR, or AR was examined by speci®c radioligand binding assays, and binding constants were calculated as described in Materials and Methods.
bResults are expressed as mean 6 SEM of four separate experiments.
cND, not detected (no signi®cant ligand binding).
Figure 3. The inhibitory effects by combina-
tion of E2, progesterone, or DHT on the
proliferation of melanoma cell lines.
WM266-4 (a), HS-15 (b), or NM26 (c) cells
were cultured with the indicated combination
of E2 (10±9 M), progesterone (10±9 M), or
DHT (10±8 M) before examining 3H-thymidine
uptake. The data are shown as percentage vs
3H-thymidine uptake of control cultures with
medium alone. Results represent the mean 6
SEM of four separate experiments. *p < 0.05 vs
control cultures, by analysis of variance with
Scheffe's multiple comparison test. The values of
3H-thymidine uptake in control cultures were
mean 6 SEM (n = 4) 19,236 6 1523, 15,231 6
1224, and 10,354 6 1194 cpm for WM266-4,
HS15, and NM26 cells, respectively.
Figure 4. Cytokine-induced recovery from
the inhibitory effects of E2, progesterone, or
DHT on the proliferation of melanoma cells.
WM266-4 (a), HS15(b), or NM26 cells (c) were
cultured in the presence or absence of E2
(10±9 M) (a), progesterone (10±9 M) (b), or DHT
(10±8 M) (c) with or without various cytokines
(each 5 ng per ml) before examining 3H-
thymidine uptake. In some experiments, the
culture of melanoma was performed in the
presence of mouse anti-IL-8 antibody or control
mouse IgG (each 10 mg per ml). The data are
shown as percentage vs 3H-thymidine uptake of
control cultures with medium alone. Results
represent the mean 6 SEM of four separate
experiments. *p < 0.05 vs control cultures and ²p
< 0.05 vs cultures of E2, progesterone, or DHT
alone, by analysis of variance with Scheffe's
multiple comparison test. The values of 3H-
thymidine uptake in control cultures were
mean 6 SEM (n = 4) 18,289 6 1626, 15,253 6
1329, and 11,385 6 1096 cpm for WM266-4,
HS15, and NM26 cells, respectively.
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expressed PR and AR, but not ER. NM26 expressed ER and AR,
but not PR. Thus the presence or absence of each hormone
receptor differed among cell lines; however, the af®nity of ER, PR,
or AR as expressed as a Kd value, was similar between each
receptor-positive cell line. The results in western blot (Fig 1) were
consistent with those in binding assays; a 65 kDa band for ER
protein was detected in WM266-4 and NM26 but not in HS15. A
114 kDa band for PR was detected in WM266-4 and HS15, and
not in NM26. A 110 kDa band for AR was detected in HS15 and
NM26, but not in WM266-4. We next examined if each hormone
may alter the growth of melanoma cell lines in a receptor-
dependent manner.
The inhibitory effects of E2, progesterone, and DHT on the
growth of melanoma cells As shown in Fig 2(a), E2 inhibited
3H-thymidine uptake of ER-positive WM266-4 and NM26 in a
concentration-dependent manner, but not that of ER-negative
HS15; percentage inhibition vs control by 10±9 M of E2 was 52%,
48%, and 2% in WM266-4, NM26, and HS15, respectively. E2
stereoisomer 17a-estradiol, known to be biologically inactive as an
estrogen, did not alter the growth of any melanoma cell lines. In
addition, ER antagonist ICI 182,780 counteracted the growth-
inhibitory effect of E2 in both ER-positive WM266-4 and NM26
cells in a concentration-dependent manner, but did not alter the
growth of ER-negative HS15 treated with E2 (Fig 2d). These
results suggest that E2 may inhibit the growth of melanoma cells
dependently on the binding to ER. Progesterone also inhibited 3H-
thymidine uptake of PR-positive WM266-4 and HS15 but not that
of PR-negative NM26 (Fig 2b); percentage inhibition by 10±9 M
of progesterone was 47%, 45%, and 3% in WM266-4, HS15, and
NM26, respectively, and the growth-inhibitory effect was not
manifested by the progesterone stereoisomer, pregnenolone. The
PR antagonist RU486 counteracted the growth inhibition by
progesterone in both WM266-4 and HS15 cells in a concentration-
dependent manner (Fig 2e). DHT also inhibited 3H-thymidine
uptake of AR-positive NM26 and HS15 in a concentration-
dependent manner, but not that of AR-negative WM266-4;
percentage inhibition by 10±8 M of DHT was 49%, 46%, and 2% in
NM26, HS15, and WM266-4, respectively, and the growth-
inhibitory effect was not mediated by DHT stereoisomer, b-
dihydrotestosterone. The AR antagonist bicaltamide counteracted
the growth inhibition by DHT in both HS15 and NM26 cells in a
concentration-dependent manner (Fig 2f). As compared with the
other two hormones, the dose±response curve for DHT shifted to
the right by 1 order, which may re¯ect the lower af®nity of AR,
i.e., larger Kd value (Table I). As 10
±9 M for E2 and progesterone,
and 10±8 M for DHT appeared to be the optimal concentrations for
growth inhibition, respectively, these concentrations were used in
further experiments.
We next examined if the combination of different hormones
may give additive or synergistic inhibition on the growth of
melanoma cells. In ER and PR-positive and AR-negative
WM266-4 (Fig 3a), the inhibitory effect by combination of E2
and progesterone was not higher than that of either hormone alone.
The addition of DHT did not alter the inhibitory effect of E2 or
progesterone alone, or that of E2 plus progesterone. Similar results
were obtained in HS15 and NM26 (Fig 3b, c). Thus the
combination of more than two different hormones neither gave
additive nor synergistic inhibition, indicating that the mechanism
for the growth inhibition may be common to E2, progesterone,
and DHT, and that the response of melanoma may be saturated by
an optimal concentration of either hormone.
The counteracting effects of IL-8 on growth inhibition by
E2, progesterone, and DHT As metastatic melanoma cells
constitutively produce various growth factors and autonomously
Table II. The effects of E2, progesterone, or DHT on the secretion of cytokines other than IL-8 in melanoma cellsa
Conditions
GROa (ng per ml) PDGF-AB (ng per ml) bFGF (ng per ml) IL-6 (ng per ml)
WM HS NM WM HS NM WM HS NM WM HS NM
Control 8.0b 2.0 6.0 0.4 0.9 0.5 0.6 0.5 0.3 0.3 0.4 0.6
E2 (10±9 M) 8.1 2.0 5.8 0.5 0.9 0.6 0.5 0.4 0.3 0.4 0.4 0.5
p (10±9 M) 8.1 2.1 5.8 0.5 0.8 0.6 0.6 0.5 0.4 0.3 0.5 0.5
DHT (10±8 M) 7.8 2.0 5.8 0.5 1.0 0.5 0.5 0.4 0.3 0.3 0.4 0.6
aWM266-4, HS15, and NM26 cells were plated, washed, and incubated with E2, progesterone, or DHT at indicated concentrations as described in Materials and
Methods. The cytokine secretion in the culture supernatants was analyzed by ELISA.
bThe results are the mean of four separate experiments and SEM are less than 8% of the means.
Figure 5. The inhibitory effects by
combination of E2, progesterone, and/or
DHT on the proliferation of melanoma cell
lines. WM266-4 (a), HS-15 (b), or NM26 cells
(c) were cultured with the indicated combination
of E2 (10±9 M), progesterone (10±9 M), and/or
DHT (10±8 M) for 24 h, and IL-8 secretion in
culture supernatants was analyzed by ELISA. The
data are shown as percentage vs IL-8 secretion in
control cultures with medium alone. Results
represent the mean 6 SEM of four separate
experiments. *p < 0.05 vs control cultures, by
analysis of variance with Scheffe's multiple
comparison test. The amounts of IL-8 secretion in
control cultures were mean 6 SEM (n = 4)
8.1 6 1.2, 7.6 6 0.9, and 5.2 6 0.6 ng per ml
for WM266-4, HS15, and NM26 cells,
respectively.
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proliferate through such growth factors, it is indicated that the
growth-inhibitory effects of E2, progesterone, and DHT may be
mediated by inhibiting the autocrine growth factor production in
melanoma. To identify the cytokine(s) that may be involved in the
growth inhibition by sex hormones, various cytokines reported as
autocrine growth factors of melanoma (Herlyn, 1990) are added to
the melanoma cells cultured with hormones, and their in¯uence on
E2, progesterone, or DHT-induced growth inhibition was
examined. Among various cytokines, only IL-8 overcame the
growth inhibition by E2 in WM266-4 (Fig 4a). When
endogenous IL-8 activity was neutralized by anti-IL-8 antibody,
the 3H-thymidine uptake of WM266-4 was reduced by 70%
compared with control, indicating that IL-8 may act as an autocrine
growth factor in WM266-4. In the presence of this antibody, E2
did not further reduce the 3H-thymidine uptake of WM266-4.
Similar results were obtained in NM26 cultured with E2 (data not
shown). These results suggest that the growth-inhibitory effect of
E2 may be mediated via IL-8 in WM266-4 and NM26. As shown
in Fig 4(b, c), IL-8 overcame the growth inhibition by
progesterone in HS15 and that by DHT in NM26. Anti-IL-8
antibody reduced the 3H-thymidine uptake of both cell lines,
suggesting that IL-8 may act as an autocrine growth factor in both
cell lines. When endogenous IL-8 was neutralized by anti-IL-8
antibody, the growth-inhibitory effects of progesterone and DHT
were not detected in HS15 and NM26, respectively. Similar results
were obtained in WM266-4 cultured with progesterone and in
HS15 cultured with DHT (data not shown). These results suggest
that IL-8 may be involved in the growth-inhibitory effects of
progesterone in HS15 and WM266-4 and those of DHT in NM26
and HS15. We then examined if E2, progesterone, or DHT may
alter IL-8 production in the three different melanoma cell lines.
The effects of sex hormones on IL-8 production in
melanoma WM266-4, HS15, and NM26 constitutively
secreted large amounts of IL-8 (5.2±8.1 ng by 5 3 104 cells). E2
reduced IL-8 secretion in ER-positive WM266-4 and NM26 by
62.5% and by 60% compared with controls, respectively, whereas it
did not alter that in ER-negative HS15 (Fig 5). Progesterone also
reduced IL-8 secretion in PR-positive WM266-4 and HS15 by
56.3% and by 61.6%, respectively, and did not affect that in PR-
negative NM26. DHT also reduced IL-8 secretion in AR-positive
HS15 and NM26 by 65.3% and by 56%, respectively, and did not
alter that in AR-negative WM266-4. In parallel with the growth
inhibition, anti-estrogen ICI 182,780 counteracted the E2-induced
inhibition of IL-8 production in WM266-4 and NM26 cells (data
not shown), and similar results were obtained for anti-progesterone
RU486 on progesterone-induced inhibition, and anti-androgen
bicaltamide on DHT-induced inhibition of IL-8 production (data
not shown). Thus E2, progesterone, or DHT inhibited IL-8
secretion in melanoma cells in a respective receptor-dependent
manner. In each melanoma cell line, the combination of more than
two different sex hormones neither gave additive nor synergistic
inhibition on the IL-8 secretion, which correlated with the
hormone-induced inhibition of 3H-thymidine uptake (Fig 3).
Though WM266-4, HS15, and NM26 constitutively secreted large
amounts of GRO-a, none of E2, progesterone, and DHT altered
the secretion of GRO-a in any cell lines. The secretion of PDGF-
AB, bFGF, and IL-6 were lower than that of IL-8 or GRO-a, and
were not affected by any hormones in any cell lines (Table II).
We then analyzed if IL-8 mRNA expression in melanoma cells
may be altered by E2, progesterone, or DHT. As analyzed by
northern blot (Fig 6a, b), WM266-4, HS15, and NM26
constitutively expressed IL-8 mRNA, and the expression was
suppressed by sex hormones in a respective receptor-dependent
manner; E2 reduced steady-state IL-8 mRNA levels of ER-positive
Figure 6. Northern blot analysis for the effects of E2,
progesterone, or DHT on IL-8 mRNA expression in melanoma
cells. WM266-4, HS15, or NM26 cells were cultured with E2
(10±9 M), progesterone (10±9 M), or DHT (10±8 M) for 8 h. Cells were
then harvested and total RNA (25 mg) from each sample was subjected
to northern blot analysis and probed for IL-8 and b-actin mRNA (a) and
the intensity of the bands were analyzed by densitometry, and the
intensity ratio was calculated (b). The data are representative of four
different experiments.
Figure 7. The inhibitory effects of E2,
progesterone, or DHT on IL-8 promoter
activities in melanoma cells. WM266-4 (a),
HS15 (b), and NM26 cells (c) were transiently
transfected with IL-8 promoter CAT reporter
constructs and cultured with indicated
combinations of E2 (10±9 M), progesterone
(10±9 M) or DHT (10±8 M). The IL-8 promoter
activity was assessed by CAT expression of the
cell lysate. The data are shown as percentage vs
CAT expression in control cultures with medium
alone. Results represent the mean 6 SEM of four
separate experiments. *p < 0.05 vs control
cultures, by analysis of variance with Scheffe's
multiple comparison test. The CAT expression in
control cultures was mean 6 SEM (n = 4)
32.4 6 3.5, 30.6 6 2.9, and 20.3 6 1.8 pg CAT
per mg protein for WM266-4, HS15, and NM26,
respectively. The CAT expression in pCAT3-
control vector was 130 6 11, 151 6 14, and
145 6 13 pg CAT per mg protein for WM266-4,
HS15, and NM26 cells, respectively. The CAT
expression by promoterless pCAT3-basic vector
was less than detectable level in all three cell lines.
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WM266-4 and NM26 and did not affect that of ER-negative
HS15. Progesterone reduced IL-8 mRNA levels of PR-positive
WM266-4 and HS15, but did not alter that of PR-negative NM26.
DHT reduced IL-8 mRNA levels of AR-positive HS15 and
NM26, and did not affect that of AR-negative WM266-4. Thus
the inhibitory effects of E2, progesterone, and DHT on IL-8
mRNA expression closely correlated with those on IL-8 protein
secretion (Fig 5), suggesting the pretranslational inhibition. We
then examined if E2, progesterone, and DHT may exert their
effects at the transcriptional level by analyzing the effects of the
hormones on the activity of IL-8 promoter.
The effects of E2, progesterone, and DHT on CAT
expression driven by IL-8 promoter WM266-4, HS15, and
NM26 were transiently transfected with plasmid containing human
IL-8 promoter driving CAT reporter gene, and the promoter
activity was assessed by the expression of CAT enzyme. Though it
is known that IL-8 promoter activity is upregulated by IL-1 or
phorbol 12-myristate 13-acetate (Mukaida et al, 1989), the
melanoma cell lines showed considerable levels of CAT
expression driven by IL-8 promoter (20.3±32.4 pg CAT per mg
protein) even in unstimulated state. As shown in Fig 7, the
constitutive activity of IL-8 promoter in each melanoma cell line
was inhibited by E2, progesterone, or DHT in a respective
receptor-dependent manner; E2 reduced IL-8 promoter activity of
ER-positive WM266-4 (Fig 7a) and NM26 (Fig 7c) by 65% and
by 60% compared with controls, respectively, and did not alter that
of ER-negative HS15 (Fig 7b). Progesterone reduced IL-8
promoter activity of PR-positive WM266-4 and HS15 by 61%
and by 60%, respectively, but did not affect that of PR-negative
NM26. DHT reduced IL-8 promoter activity of AR-positive
HS15 and NM26 by 62% and by 58%, respectively, and did not
affect that of AR-negative WM266-4. The combination of more
than two different sex hormones neither gave additive nor
synergistic inhibition on IL-8 promoter activity in each
melanoma cell line, which was consistent with the sex hormone-
induced inhibition of IL-8 secretion (Fig 5). These results suggest
that E2, progesterone, and DHT may inhibit IL-8 production at
the transcriptional level in a respective receptor-dependent manner.
To con®rm that the hormone-induced transcriptional inhibition
may be mediated via the respective hormone receptor, we
transiently cotransfected ER, PR, or AR-negative melanoma
with the respective receptor expression plasmid together with IL-
8/CAT construct, and examined if E2, progesterone, or DHT may
inhibit the IL-8 promoter activity in the respective receptor-
transfected cells. Transient transfection of AR-negative WM266-4
with wild-type AR vector resulted in the measurable 3H-R1881
binding; Kd = 1.1 nM and Bmax = 17.3 fmol protein per mg. On
the other hand, WM266-4 transfected with hormone-binding
domain-deleted mutant AR (Fig 8g) did not show signi®cant
binding to 3H-R1881. By western blotting, the expression of wild-
type and mutant AR was con®rmed as 114 kDa and 87 kDa band,
respectively (Fig 8d). The IL-8 promoter activity in wild-type
AR-transfected WM266-4 was not reduced compared with empty
vector pSG5-transfected cells (Fig 8a), suggesting that the
overexpression of wild-type AR itself may not inhibit IL-8
promoter activity. In the wild-type AR-transfected WM266-4
(Fig 8a), however, DHT reduced IL-8 promoter activity by 71.4%
compared with control cultured with medium alone whereas in
WM266-4 transfected with hormone-binding domain-deleted
mutant AR, DHT did not reduce the IL-8 promoter activity.
Thus wild-type AR, transfected into melanoma, could repress IL-8
promoter activity in the presence of DHT, and the repression
required the binding of DHT to AR. Similarly, transient
transfection of ER-negative HS15 with wild-type ER resulted in
the measurable 3H-E2 binding; Kd = 0.4 nM and Bmax = 15.1
fmol per mg protein. On the other hand, HS15 transfected with
hormone-binding domain-truncated mutant ER (Fig 8h) did not
show signi®cant binding to 3H-E2. By western blotting, the
expression of wild-type and mutant ER was con®rmed as 66 kDa
and 37 kDa band, respectively (Fig 8e). In wild-type ER-
transfected HS15 (Fig 8b), E2 inhibited IL-8 promoter activity
by 63.6% compared with control, but did not alter that in HS15
transfected with hormone-binding domain-deleted mutant ER,
indicating that E2-induced transrepression was dependent on E2-
binding to ER. Transient transfection of PR-negative NM26 with
wild-type PR resulted in the measurable 3H-R5020 binding;
Kd = 0.45 nM and Bmax = 16.5 fmol protein per mg. On the
other hand, NM26 transfected with hormone-binding domain-
truncated mutant PR (Fig 8i) did not show signi®cant binding to
3H-R5020. By western blotting, the expression of wild-type and
mutant PR was con®rmed as 110 kDa and 79 kDa band,
respectively (Fig 8f). Progesterone inhibited IL-8 promoter
activity by 68.2% compared with control in the wild-type PR-
transfected NM26, but did not affect that in NM26 transfected with
hormone-binding domain-truncated mutant PR, indicating that
progesterone-induced transrepression was dependent on
Figure 8. The inhibition by E2, progesterone,
or DHT on IL-8 promoter activity in wild-
type or mutant ER, PR, or AR-transfected
melanoma cells. WM266-4 (a), HS15 (b), or
NM26 (c) cells were cotransfected with IL-8
promoter CAT reporter construct and either
empty vector pSG5 or wild type (WT) or
hormone-binding domain-deleted mutant (MU)
AR (a), ER (b), or PR (c) expression vector, and
incubated with or without DHT 10±8 M (a), E2
10±9 M (b), or progesterone 10±9 M (c). The IL-8
promoter activity was assessed by CAT expression
of the cell lysate. Results represent the
mean 6 SEM of four separate experiments. *p
< 0.05 vs wild-type receptor-transfected cells
cultured with medium alone, by analysis of
variance with Scheffe's multiple comparison test.
The transfected wild-type and mutant AR (d), ER
(e), and PR (f) were veri®ed for expression by
western blot. The structure of wild-type and
mutant receptors is presented in (g±i). Regions
A/B, C, D, and E represent the amino-terminal,
DNA-binding, hinge, and the hormone-binding
domains, respectively. The number of amino acid
residues and restriction enzyme-cut sites are
indicated.
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progesterone binding to PR. (Fig 8c). These results suggest that the
transcriptional repression by E2, progesterone, and DHT may be
speci®cally mediated by binding to the respective receptor.
To characterize the DNA sequences involved in hormone-
induced transcriptional repression on the IL8 gene, we used CAT
expression plasmids linked to serially 5¢-deleted IL-8 promoters,
and compared the effects of hormones on the activities of the
deleted promoters. In transfected WM266-4 cells, the basal
promoter activity of ±272 CAT (containing ±272 to +44 bp of
IL-8 promoter) was not different from that of ±546 CAT, and both
were repressed by E2 (Fig 9a). The basal promoter activity of ± 98
CAT was reduced as compared with that of ±546 or ±272 CAT,
indicating that the sequences between ±272 to ±99 bp may partially
direct the constitutive promoter activity. The promoter activity of
±98 CAT, however, was still repressed by E2; percentage inhibition
by E2 was 61% and 61.5% in ±272 and ±98 CAT-transfected cells,
respectively. These results indicate that the sequences up to ±98 bp
may be dispensable for the transcriptional repression by E2. When
WM266-4 was transfected with ±62 CAT, the basal promoter
activity was further reduced, and was not at all repressed by E2.
These results suggest that the sequences between ±98 and ±63 bp
may partially direct the constitutive IL-8 transcription and may be
mainly involved in the E2-induced transcriptional repression.
Similar results were obtained in the 5¢-deleted IL-8/CAT-
transfected and E2-incubated NM26 cells (data not shown). In
the 5¢-deleted IL-8/CAT-transfected and progesterone-treated
HS15 (Fig 9b) or DHT-treated NM26 (Fig 9c), the deletion up
to ±98 bp of IL-8 promoter preserved the repression by proges-
terone or DHT, respectively, whereas deletion up to ±62 bp
resulted in the complete loss of the repression. Similar results were
obtained in the 5¢-deleted IL-8/CAT-transfected and progester-
one-treated WM266-4 or DHT-treated HS15 (data not shown).
These results suggest that the sequences between ±98 and ±63 bp
are mainly involved in the hormone-induced repression of IL-8
transcription in melanoma.
DISCUSSION
This study demonstrated that E2, progesterone, and DHT inhibited
the growth of metastatic melanoma WM266-4, HS15, and NM26
by inhibiting IL-8 transcription. The inhibitory effect of each
hormone was mediated via the respective receptor. The growth of
the other melanoma cell lines was also receptor-dependently
inhibited by sex hormones via the suppression of IL-8 production;
among melanoma TO 23, HO 14, and YN 115 established in our
laboratory, the presence of ER and E2-induced growth inhibition
via IL-8 were only seen in TO 23, but not in the others. The
presence of PR and progesterone-induced growth inhibition via
IL-8 were only seen in HO 14 and not in the others. The presence
of AR and DHT-induced growth inhibition via IL-8 were only
seen in YN 115 and not in the others (data not shown). The
previous study also reported that progesterone inhibited basal and
IL-1-induced IL-8 mRNA expression in rat uterine ®broblasts (Ito
et al, 1994); however, it is unknown how E2, progesterone, or
DHT may suppress IL-8 transcription. It is likely that the three
different hormones may exert their effects by a common mech-
anism as the combination of more than two hormones gave neither
synergistic nor additive effects. One possible mechanism is that each
hormone-bound receptor may inhibit the transcriptional activity
and/or DNA binding of transcriptional activators on the IL-8
promoter. It is known that several transcriptional activators co-
operate with one another through protein±protein interaction to
activate the IL-8 promoter (Roebuck, 1999). The sequences from
±98 to ±63 bp appeared to direct the constitutive IL-8 transcription
in melanoma, and may be the main target for hormone-induced
transcriptional repression. This region includes adjacent elements
for C/EBP (±94 to ±81) and NF-kB (±80 to ±70). It is reported that
NF-kB subunit p65 and C/EBPb form a ternary complex with this
region of the IL-8 promoter, which results in synergistic
transcriptional activation (Kunsch et al, 1994). It is thus hypothe-
sized that each sex hormone/receptor complex may interact with
NF-kB and/or C/EBP family proteins, and alter their conform-
ation, which may repress their DNA-binding and/or the
cooperative transcriptional activity on IL-8 promoter. The previous
studies reported the direct protein±protein interaction of ER with
NF-kB p65 and with C/EBPb(Stein and Yang, 1995). PR and AR
directly interacted with NF-kB p65 and repressed its transcriptional
activity on several gene promoters (Kalkhoven et al, 1996; McKay
and Cidlowski, 1999). E2 and DHT also inhibited the transcrip-
tional activity of NF-kB via IkBa (Keller et al, 1996; Sun et al,
1998) IkBa is constitutively associated with NF-kB in cytosol and
inhibits its translocation to the nucleus where DNA binding occurs.
E2 and DHT repressed the degradation of IkBa, and maintained
the IkBa protein level, and thus inhibited the transcriptional
activity of NF-kB. As dexamethasone and 1a,25-dihydroxyvitamin
D3 suppressed IL-8 transcription by inhibiting the DNA binding of
NF-kB in a glioblastoma cell line (Mukaida et al, 1994; Harant
et al, 1997), a similar mechanism is implicated for E2, progesterone,
or DHT. DNA-binding activity and mRNA levels of NF-kB
subunits p65 and p50 are constitutively enhanced in melanomas
compared with normal melanocytes (Meyskens et al, 1999), which
may be related to the constitutively high level of IL-8 production in
melanoma. Taken together, it is hypothesized that NF-kB may be
one of the main targets for the sex hormone-induced transcriptional
repression. It is also likely that C/EBP may be the target. C/EBP is
known to mainly mediate the constitutive IL-8 transcription
without any stimuli (Wu et al, 1997). DHT-bound AR also
suppressed the C/EBP-mediated transcription on rat dehydroe-
piandrosterone sulfotransferase promoter (Song et al, 1998). In the
present study, the deletion of ± 272 to ± 99 bp on IL-8 promoter
greatly reduced the constitutive promoter activity (Fig 9). As this
region contains AP-1 element (±126 to ±120) (Mukaida et al,
1989), AP-1 may partially confer the constitutive IL-8 transcription
in melanoma. A previous study also reported that the constitutive
DNA-binding activity of AP-1 was higher in melanomas than in
melanocytes (Meyskens et al, 1999). It is known that AP-1 as well
as C/EBP physically interacts with NF-kB and synergistically
activates IL-8 transcription (Stein et al, 1993; Roebuck, 1999). AP-
1, however, may not be involved in hormone-induced transcrip-
tional repression as the repression was not abolished by the deletion
of the region containing ±126 to ±120 (Fig 9).
Figure 9. The in¯uence of 5¢-deletion on E2,
progesterone, or DHT-induced inhibition of
IL-8 promoter activity. WM266-4 (a), HS15
(b), or NM26 cells (c) were transfected with CAT
reporter vectors into which various 5¢-deleted
IL-8 promoters were cloned. After transfection,
the cells were incubated with or without E2
(10±9 M) (a), progesterone (10±9 M) (b), or DHT
(10±8 M) (c) for 24 h. CAT expression was then
analyzed.
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In addition to the inhibition of transcriptional activators, sex
hormones may promote the synthesis and/or activity of repressor(s)
for IL-8 transcription. C/EBP site (±94 to ±81) on IL-8 promoter
overlaps with an element for Oct-1 (±91 to ±84) (Roebuck, 1999),
and the binding of Oct-1 displaces C/EBP from this element and
thus represses the constitutive IL-8 transcription (Wu et al, 1997).
Thus sex hormones may promote such transcriptional repression by
Oct-1. On the other hand, Oct-1 acts as a transcriptional activator
on mouse mammary tumor virus promoter (Prefontaine et al,
1999). It is known that progesterone/PR complex binds to the
hormone response element on this promoter, and facilitates the
binding of Oct-1 to its consensus element, and thus promotes its
transcriptional activation (Prefontaine et al, 1999). There have been
no reports, however, that the hormone-bound receptor may
enhance the repressor activity of Oct-1, and this possibility should
further be investigated. Another possible mechanism is that the sex
hormone-bound receptor may directly interact with the IL-8
promoter and thus displace certain transcriptional activator(s) from
the respective element(s). This possibility is, however, rather
unlikely as the sequences responsible for transcriptional repression
(±98 to ±63) contain no consensus hormone response elements.
Previous studies also reported that E2-bound ER repressed IL-6
promoter activity (Pottratz et al, 1994) and DHT-bound AR
repressed rat dehydroepiandrosterone sulfotransferase promoter
activity (Song et al, 1998), both without direct interaction with
DNA. IL-8 promoter contains the binding site for PR and AR at ±
330 to ±325 (Mukaida et al, 1989); however, this element did not
appear to mediate the transcriptional repression by sex hormones as
the repression was not abolished by the deletion of this element-
containing region (±546 to ±273) (Fig 9). It is also speculated that
the other unde®ned transcriptional activators or repressors may be
the target for sex hormones. Further studies should elucidate the
target molecule(s) and the precise mechanism for transcriptional
repression by sex hormones on the IL-8 promoter.
In this study, WM266-4, HS15, and NM26 appeared to
proliferate by an autocrine loop of IL-8 as their growth was greatly
inhibited by the anti-IL-8 antibody (Fig 4). Previous reports also
con®rmed the role of IL-8 as an autocrine growth factor of
melanoma, and the correlation of its expression with metastatic
potential (Schadendorf et al, 1993; Andrew et al, 1995; Luca et al,
1997). Certain melanomas, however, may grow independently
from IL-8. E2, progesterone, or DHT may enhance the growth of
certain melanomas by promoting the production of growth factors
different from IL-8, such as transforming growth factor-b, the
production of which is enhanced by DHT (Pederson et al, 1999).
Thus further studies should elucidate the hormonal effects on the
IL-8-independent melanomas.
This study shows that these sex hormones can be used for the
treatment of patients with melanoma, and that the therapeutic
ef®ciency may depend on the respective receptors. The combin-
ation of sex hormones with other chemotherapeutic agents may
prevent postoperational recurrence or metastasis of melanoma. This
study, however, was performed on the established melanoma cell
lines and thus the results may be valid only in the in vitro limited
settings. Similar examination should be extended into primary
tumor cell cultures from freshly biopsied material as the hormonal
effects on such material may be more close to those in vivo. To date,
several clinical trials have been done on advanced melanomas by
hypophysectomy or the administration of testosterone, ethinyles-
tradiol (Bodenham and Hale, 1972), 6a-methylpregn-4-
ene,3,11,20-trione (Johnson et al, 1966), medroxyprogesterone
acetate (Baretta et al, 1979), or recently tamoxifen (Neifeld, 1996;
Chapman et al, 1999; Creagan et al, 1999; Propper et al, 2000);
however, only limited subsets of patients were responsive to
hormonal therapy, and the response did not correlate with the
presence of hormone receptor in their melanoma cells (Linder and
Borden, 1997; Karakosis et al, 1980; Neifeld and Lippman, 1980;
Neifeld, 1996). These indicate nonreceptor-mediated hormonal
effects or the effects via alternate receptors other than conventional
intracellular counterparts and/or indirect growth regulation via the
other hormone-responding cells. It is reported that E2 disrupts the
cytoplasmic microtubule network and thus inhibited the growth of
both ER-positive and -negative human breast cancer cell lines,
indicating the receptor-independent effect (Aizu-Yokota et al,
1994). The recent studies also suggest that membrane-associated
receptors, structurally similar to (Papas et al, 1995) or different from
conventional intracellular counterparts (Bression et al, 1986), may
exist and mediate some rapid, nontranscriptional actions such as
calcium in¯ux (Blackmore et al, 1990) or the activation of tyrosine
kinase (Migliaccio et al, 1996). In addition to the high-af®nity
receptors, different hormone-binding sites are identi®ed; type II
estrogen binding sites exhibit lower af®nity but higher capacity for
estrogen compared with ER, and are detected in several human
melanoma cells, and may be involved in the in vitro hormonal
growth regulation on those cells (Piantelli et al, 1995). The
unconventional receptor-mediated hormonal effects in vivo should
further be clari®ed.
Melanoma-derived growth factors act on adjacent stromal cells
such as endothelial cells, macrophages, ®broblasts, or lymphocytes,
whereas these cells in turn produce various factors that regulate
tumor growth, angiogenesis, adhesion, motility, or metastasis (Shih
and Herlyn, 1993; Laza-Molnar et al, 2000). Sex hormones may
alter the autocrine and/or paracrine production of angiogenic
factors, such as vasculoendothelial growth factor (Hyder et al,
1996). Sex hormones may also alter the expression of adhesion
molecules (Lupetti et al, 1996), or activity of proteolytic enzymes in
melanoma (Herlyn, 1990; Lazar-Molnar et al, 2000). Sex hormones
also affect the host immune responses to melanoma by natural killer
cells (Hanna and Schneider, 1983) or macrophages (Ackermann
et al, 1986). We are now studying the in vivo effects of sex
hormones on the invasion and metastasis of presently used
melanomas in athymic nude mice. Further studies should also
elucidate the growth-regulatory effects of sex hormones on the
coculture of melanoma with endothelial cells, macrophages, or
®broblasts in vitro.
We thank Dr. Tomoo Tanase (Takara Gene Analysis Center) for the synthesis of
pIL-8 CAT. This work is supported in part by the grant from the Japanese Ministry
of Education (12770459) and the aid from KANZAWA Medical Research
Foundation.
REFERENCES
Ackermann MF, Mark R, Chakraborty PR, Morahan PS: Effects of diethylstilbestrol
on propionibacterium acnes. Immunomodulation: inhibition of macrophage
activation and antitumor activity. J Leukocyte Biol 40:549±559, 1986
Aizu-Yokota E, Ichinoseki K, Sato Y: Microtubule disruption induced by estradiol in
estrogen receptor-positive and -negative human breast cancer cell lines.
Carcinogenesis 15:1875±1879, 1994
Andrew PJ, Harant H, Lindley IJD: Nitric oxide regulates IL-8 expression in
melanoma cells at the transcriptional level. Biochem Biophys Res Commun
214:949±956, 1995
Baker FL, Spitzer G, Ajani JA, et al: Drug and radiation sensitivity measurements of
successful primary monolayer culturing of human tumor cells using cell-
adhesive matrix and supplemented medium. Cancer Res 46:1263±1274, 1986
Baretta G, Taibadon D, Fossati P: Clinical evaluation of medroxyprogesterone
acetate (MAP) in malignant melanoma. Cancer Treat Rep 63:1200, 1979
Blackmore PF, Beebe SJ, Danforth DR, Alexander N: Progesterone and 17a-
hydroxyprogesterone. Novel stimulators of calcium in¯ux in human sperm. J
Biol Chem 265:1376±1380, 1990
Bodenham DC, Hale B. Malignant melanoma. In: Stoll BA (ed.). Endocrine Therapy in
Malignant Disease. London: W.B. Saunders, 1972, pp 377±383
Bression D, Michard M, le Dafniet M, Pagesy P, Peillon F: Evidence for a speci®c
estradiol binding site on rat pituitary membranes. Endocrinology
119:1048±1051, 1986
Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ: Cell surface antigens of
human malignant melanoma: Mixed hemadsorption assays for humoral
immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA
73:3278±3282, 1976
Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ: Cell surface antigens of
human malignant melanoma: Mixed hemadsorption assays for humoral
immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA
73:3278±3282, 1976
Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial
282 KANDA AND WATANABE THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
of the Dartmouth regimen versus dacarbazine in patients with metastatic
melanoma. J Clin Oncol 17:2745±2751, 1999
Cobb JP, McGrath A: Brief communication: In vitro effects of melanocyte-
stimulating hormone, adrenocorticotropic hormone, 17b-estradiol, or
testosterone propionate on Cloudman S91 melanoma cells. J Natl Cancer Inst
52:567±570, 1974
Cohen C, DeRose PB, Campbell WG, Schlosnagle DC, Sgoutas D: Estrogen
receptor status in malignant melanoma. Am J Dermatopathol 12:562±564, 1990
Creagan ET, Suman VJ, Dalton RJ, et al: Phase III clinical trial of the combination of
cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients
with advanced malignant melanoma. J Clin Oncol 17:1884±1890, 1999
Dorn PL, Derse D: cis- and trans-acting regulation of gene expression of equine
infectious anemia virus. J Virol 62:3522±3526, 1988
Driscoll MS, Grin-Jorgensen CM, Grant-Kels JM: Does pregnancy in¯uence the
prognosis of malignant melanoma? J Am Acad Dermatol 29:6119±6630, 1993
Duncan LM, Travers RL, Koerner FC, Mihm MC Jr, Sober AJ: Estrogen and
progesterone receptor analysis in pregnancy-associated melanoma: absence of
immunohistochemically detectable hormone receptors. Hum Pathol 25:36±41,
1994
Ferno M, Borg A, Ingvar C, Jonsson PE: Estrogen receptor and binding site for
estramustine in metastatic malignant melanoma. Anticancer Res 7:741±744, 1987
Feucht KA, Walker MJ, Das Gupta TK, Beattie CW: Effect of 17 b-estradiol on the
growth of estrogen receptor-positive human melanoma in vitro and in athymic
mice. Cancer Res 48:7093±7101, 1988
Green S, Walter P, Kumar V, Krust A, Bornert J-M, Argos P, Chambon P: Human
oestrogen receptor cDNA. sequence, expression and homology to v-erb-A.
Nature 320:134±139, 1986
Green S, Issemann I, Sheer E: A versatile in vivo eukaryotic expression vector for
protein engineering. Nucleic Acids Res 16:369, 1988
Hanna N, Schneider M: Enhancement of tumor metastasis and suppression of natural
killer cell activity by b-estradiol treatment. J Immunol 130:974±980, 1983
Harant H, Andrew PJ, Reddy S, Foglar E, Lindley IJD: 1a,25-Dihydroxyvitamin D3
and a variety of its natural metabolites transcriptionally repress nuclear-factor-
kB-mediated interleukin-8 expression. Eur J Biochem 250:63±71, 1997
Herlyn M: Human melanoma: Development and progression. Cancer Metastasis Rev
9:101±112, 1990
Holly EA: Melanoma and pregnancy. Recent Results Cancer Res 102:118±126, 1986
Hyder SM, Stancel GM, Chiapetta C, Murthy L, Boettger-Tong HL, Makela S:
Uterine expression of vascular endothelial growth factor is increased by
estradiol and tamoxifen. Cancer Res 56:3954±3960, 1996
Ito A, Imada K, Sato T, Kubo T, Matsushima K, Mori Y: Suppression of interleukin
8 production by progesterone in rabbit uterine cervix. Biochem J 301:183±186,
1994
Johnson RP, Bisel H, Andrews N, et al: Phase I clinical study of 6a-methylpregn-4-
ene-3,11,20-trione (NSC-17256). Cancer Chemother Rep 50:671±673, 1966
Kalkhoven E, Wissink S, van der Saag PT, van der Burg B: Negative interaction
between the RelA (p65) subunit of NF-kB and the progesterone receptor. J
Biol Chem 271:6217±6224, 1996
Karakosis CP, Lopez RE, Bhakoo HS, Rosen F, Moore R, Carison M: Estrogen and
progesterone receptors and tamoxifen in malignant melanoma. Cancer Treat Rep
64:819±827, 1980
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P:
Two distinct estrogen-regulated promoters generate transcripts encoding the
two functionally different human progesterone receptor forms A and B. EMBO
J 9:1603±1614, 1990
Keller ET, Chang C, Ershler WB: Inhibition of NFkB activity through maintenance
of IkBa levels contributes to dihydrotestosterone-mediated repression of the
interleukin-6 promoter. J Biol Chem 271:26267±26275, 1996
Kuenen-Boumeester V, van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn
JGM, Henzen-Logmans SC: The clinical signi®cance of androgen receptors in
breast cancer and their relation to histological and cell biological parameters.
Eur J Cancer 32:1560±1565, 1996
Kunsch C, Lang RK, Rosen CA, Shannon F: Synergistic transcriptional activation of
the IL-8 gene by NF-kB p65 (RelA) and NF-IL-6. J Immunol 153:153±164,
1994
Lazar-Molnar E, Hegyesi H, Toth S, Falus A: Autocrine and paracrine regulation by
cytokines and growth factors in melanoma. Cytokine 12:547±554, 2000
Linder DJ, Borden EC: Synergistic antitumor effects of a combination of interferon
and tamoxifen on estrogen receptor-poritive and receptor-negative human
tumor cell lines in vivo and in vitro. J Interferon Cytokine Res 17:681±693, 1997
Lopez RE, Bhakoo H, Paolini NS, Rosen F, Holyoke ED, Goldrosen MH: Effect of
estrogen on the growth of B-16 melanoma. Surg Forum 29:153±154, 1978
Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M: Expression of
interleukin-8 by human melanoma cells up-regulates MMP-2 activity and
increases tumor growth and metastasis. Am J Pathol 151:1105±1113, 1997
Lupetti R, Mortarini R, Panceri P, Sensi M, Anichini A: Interaction with ®bronectin
regulates cytokine gene expression in human melanoma cells. Int J Cancer
66:110±116, 1996
Mackie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N: For the world
health organization melanoma programme: Lack of effect of pregnancy on the
outcome of melanoma. Lancet 337:653±655, 1991
McKay LI, Cidlowski JA: Molecular control of immune/in¯ammatory responses:
interactions between nuclear factor-kB and steroid receptor-signaling
pathways. Endocr Rev 20:435±459, 1999
Meyskens FL Jr, Buckmeier JA, McNulty SE, Tohidan NB: Activation of nuclear
factor-kB in human metastatic melanoma cells and the effect of oxidative stress.
Clin Cancer Res 5:1197±1202, 1999
Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E,
Auricchio F: Tyrosine kinase/p21ras/MAP-kinase pathway activation by
estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292±1300, 1996
Mukaida N, Shiroo M, Matsushima K: Genomic structure of the human monocyte-
derived neutrophil chemotactic factor IL-8. J Immunol 143:1366±1371, 1989
Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K:
Novel mechanism of glucocorticoid-mediated gene repression. J Biol Chem
269:13289±13295, 1994
Neifeld JP: Endocrinology of melanoma. Semin Surg Oncol 12:402±406, 1996
Neifeld JP, Lippman ME: Steroid hormone receptors and melanoma. J Invest Dermatol
74:379±381, 1980
Pack GT, Scharnagel M: The prognosis for malignant melanoma in the pregnant
woman. Cancer 4:324±334, 1951
Papas TC, Gametchu B, Watson CS: Membrane estrogen receptors identi®ed by
multiple antibody labeling and impeded-ligand binding. FASEB J 9:404±410,
1995
Pederson L, Kremer M, Judo J, Pascoe D, Spelsberg TC, Riggs BL, Oursler MJ:
Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc
Natl Acad Sci USA 96:505±510, 1999
Piantelli M, Maggiano N, Ricci R, et al: Tamoxifen and quercetin interact with type
II estrogen binding sites and inhibit the growth of human melanoma cells. J
Invest Dermatol 105:248±253, 1995
Pottratz ST, Bellido T, Mocharia H, Crabb D, Manolagas SC: 17b-estradiol inhibits
expression of human interleukin-6 promoter-receptor constructs by a receptor-
dependent mechanism. J Clin Invest 93:944±950, 1994
Prefontaine GG, Walther R, Gif®n W, Leimieux ME, Pope L, Hache RJG: Selective
binding of steroid hormone receptors to octamer transcription factors
determines transcriptional synergism at the mouse mammary tumor virus
promoter. J Biol Chem 274:26713±26719, 1999
Proctor JW, Auclair BG, Stokowski L: Brief communication: Endocrine factors and
the growth and spread of B16 melanoma. J Natl Cancer Inst 57:1197±1198,
1976
Propper DJ, Braybrooke JP, Levitt NC, et al: Phase II study of second-line therapy
with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen)
chemotherapy in patients with malignant melanoma previously treated with
dacarbazine. Br J Cancer 82:1759±1763, 2000
Rampen F: Malignant melanoma: sex differences in survival after evidence of distant
metastasis. Br J Cancer 42:52±57, 1980
Roebuck KA: Regulation of interleukin-8 gene expression. J Interferon Cytokine Res
19:429±438, 1999
Rosenberg JC, Assimacopoulos C, Rosenerg SA: The malignant melanoma of
hamsters: III. Effects of sex and castration on the growth of the transplanted
tumor. Ann N Y Acad Sci 100:297±296, 1963
Scatchard G: The attractions of proteins for small molecules and ions. Ann N Y Acad
Sci 51:660±672, 1949
Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM:
IL-8 produced by human malignant melanoma cells in vitro is an essential
autocrine growth factor. J Immunol 151:2667±2675, 1993
Schleicher RL, Hitsberger MH, Beattie CW: Inhibition of hamster growth by
estrogen. Cancer Res 47:453±459, 1987
Shaw HM, Milton GW, Farrago G, McCarthy WH: Endocrine in¯uences on
survival from malignant melanoma. Cancer 42:669±677, 1978
Shih I-M, Herlyn M: Role of growth factors and their receptors in the development
and progression of melanoma. J Invest Dermatol 100:196S±203S, 1993
Shiu MH, Schottenfeld D, Maclean B, Fortner JG: Adverse effect of pregnancy on
melanoma. A reappraisal. Cancer 37:181±187, 1976
Simental JA, Sar M, Lane MV, French FS, Wilson EM: Transcriptional activation and
nuclear targeting signals of the human androgen receptor. J Biol Chem
266:510±518, 1991
Song CS, Jung MH, Kim SC, Hassan T, Roy AK, Chattejee B: Tissue-speci®c and
androgen-repressible regulation of the rat dehydroepiandrosterone
sulfotransferase gene promoter. J Biol Chem 273:21856±21866, 1998
Stein B, Baldwin AS Jr, Ballard DW, Greene WC, Angel P, Herrlich P: Cross-
coupling of the NF-kB p65 and Fos/Jun transcription factors produces
potentiated biological function. EMBO J 12:3879±3891, 1993
Stein B, Yang MX: Repression of the interleukin-6 promoter by estrogen receptor is
mediated by NF-kB and C/EBPb. Mol Cell Biol 15:4971±4979, 1995
Sun WH, Keller ET, Stebler BS, Ershler WB: Estrogen inhibits phorbol ester-
induced IkBa transcription and protein degradation. Biochem Biophys Res
Commun 244:691±695, 1998
Swami S, Krishnan AV, Feldman D: 1a,25-dihydroxyvitamin D3 down-regulates
estrogen receptor abundance and suppresses estrogen actions in MCF-7 human
breast cancer cells. Clin Cancer Res 6:3371±3379, 2000
Walker BJ, Beattie CW, Patel MK, Ronan SM, Das Gupta TK: Estrogen receptor in
malignant melanoma. J Clin Oncol 5:1256±1261, 1987
Wong JH, Sterns EH, Kopald KH, Nizze JA, Morton DL: Prognostic signi®cance of
pregnancy in stage I melanoma. Arch Surg 124:1227±1231, 1989
Wu GD, Lai EJ, Huang N, Wen X: Oct-1 and CCAAT/enhancer-binding protein
(C/EBP) bind to overlapping elements within the interleukin-8 promoter. J
Biol Chem 272:2396±2403, 1997
Zachariae COC, Thestrup-Pedersen K, Matsushima K: Expression and secretion of
leukocyte chemotactic cytokines by normal human melanocytes and melanoma
cells. J Invest Dermatol 97:593±599, 1991
Zhu W, Smith A, Young YF: A nonsteroidal anti-in¯ammatory drug, ¯ufenamic
acid, inhibits the expression of the androgen receptor in LNCaP cells.
Endocrinology 140:5451±5454, 1999
VOL. 117, NO. 2 AUGUST 2001 SEX HORMONES SUPPRESS THE GROWTH OF MELANOMA 283
